BioSpace News Archive

Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 , at 2:00 p.m. EST.

Symptoms of Long COVID, Like Multi-Site Pain, Fatigue and Insomnia, are the Hallmarks of Chronic Pain Syndromes Like Fibromyalgia and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).

BioInvent made significant advances in 2022, further developing our exciting pipeline of novel and first-in-class immuno-modulatory antibodies for cancer therapy and substantially reinforcing the company’s financial position.

Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron announce the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy, an orphan, tau-related disease with a high unmet medical need.

MannKind Corporation (Nasdaq: MNKD) announced today that it will present an oral presentation describing meal challenge results at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin February 22-25.

CLEARA Biotech B.V. (“Cleara” or the “Company”) today announced that immunotherapy and oncology expert Dr. Nicholas J. Sarlis has been appointed as the company’s Chief Medical Officer (CMO) and Head of Clinical Development.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022.

Affimed N.V. announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.

Teleflex Incorporated, a leading global provider of medical technologies, announced key milestones in the release of two new catheters: the U.S. Food and Drug Administration 510 clearance of the Triumph™ Catheter, and the first clinical use of GuideLiner® Coast™ Catheter.

BiomX Inc. today announced that it has entered into a securities purchase agreement (“SPA”) with a select group of institutional and individual investors.